• Ocumension Therapeutics’ China regulator accepted an NDA for OT-301 to lower intraocular pressure in open-angle glaucoma or ocular hypertension.
• Filing backed by Phase III Mont Blanc data; Denali Phase III met non-inferiority versus latanoprost in August 2025.
• OT-301 is a nitric oxide-donating prostaglandin analog co-developed with Nicox, which invented the compound.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ocumension Therapeutics published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260911-12328596), on September 10, 2026, and is solely responsible for the information contained therein.